S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products. The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.
Frequently asked questions
What sector does S.Biomedics Co. Ltd. (304360) operate in?
S.Biomedics Co. Ltd. belongs to the Other sector and operates in the Biotechnology industry.
What is S.Biomedics Co. Ltd. (304360) current stock price?
As of the latest data, S.Biomedics Co. Ltd. stock price is ₩20,450, with a previous close of ₩20,050. S.Biomedics Co. Ltd. gained ₩400 in the last trading session, representing a 2% increase.
What is S.Biomedics Co. Ltd. (304360) current market capitalization?
S.Biomedics Co. Ltd. market cap is approximately 253.28 billion.
What is S.Biomedics Co. Ltd. (304360) EBITDA?
S.Biomedics Co. Ltd. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.04 billion.
Does S.Biomedics Co. Ltd. (304360) pay dividends?
No. S.Biomedics Co. Ltd. does not pay a dividend.
What is S.Biomedics Co. Ltd. (304360) beta (volatility) score?
S.Biomedics Co. Ltd. has a beta of 1.457, suggesting it is more volatile than the market.
